Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib.
Stefanini B, Tovoli F, Trevisani F, Marseglia M, Di Costanzo GG, Cabibbo G, Sacco R, Pellizzaro F, Pressiani T, Chen R, Ponziani FR, Foschi FG, Magini G, Granito A, Piscaglia F; Italian Liver Cancer (ITA.LI.CA) group. Stefanini B, et al. Among authors: di costanzo gg. Intern Emerg Med. 2024 Mar 29. doi: 10.1007/s11739-024-03578-8. Online ahead of print. Intern Emerg Med. 2024. PMID: 38551755
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Sansone V, Tovoli F, Casadei-Gardini A, Di Costanzo GG, Magini G, Sacco R, Pressiani T, Trevisani F, Rimini M, Tortora R, Nardi E, Ielasi L, Piscaglia F, Granito A. Sansone V, et al. Among authors: di costanzo gg. Clin Transl Gastroenterol. 2021 Jan 14;12(1):e00286. doi: 10.14309/ctg.0000000000000286. Clin Transl Gastroenterol. 2021. PMID: 33443944 Free PMC article.
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG. Trevisani F, et al. Among authors: di costanzo gg. J Cancer Res Clin Oncol. 2018 Feb;144(2):403-414. doi: 10.1007/s00432-017-2556-6. Epub 2017 Dec 16. J Cancer Res Clin Oncol. 2018. PMID: 29249005 Free article.
Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Sansone V, Tovoli F, Casadei-Gardini A, Di Costanzo GG, Magini G, Sacco R, Pressiani T, Trevisani F, Rimini M, Tortora R, Nardi E, Ielasi L, Piscaglia F, Granito A. Sansone V, et al. Among authors: di costanzo gg. Clin Transl Gastroenterol. 2021 Apr 27;12(5):e00335. doi: 10.14309/ctg.0000000000000335. Clin Transl Gastroenterol. 2021. PMID: 33904523 Free PMC article. No abstract available.
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma.
Guarino M, Cossiga V, Capasso M, Mazzarelli C, Pelizzaro F, Sacco R, Russo FP, Vitale A, Trevisani F, Cabibbo G; The Associazione Italiana Per Lo Studio Del Fegato AISF HCC Special Interest Group. Guarino M, et al. J Clin Med. 2022 Jul 31;11(15):4475. doi: 10.3390/jcm11154475. J Clin Med. 2022. PMID: 35956091 Free PMC article. Review.
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments.
Tovoli F, Pallotta DP, Sansone V, Iavarone M, De Giorgio M, Ielasi L, Di Costanzo GG, Giuffrida P, Sacco R, Pressiani T, Di Donato MF, Trevisani F, Fagiuoli S, Piscaglia F, Granito A. Tovoli F, et al. Among authors: di costanzo gg. Transplantation. 2023 Jan 1;107(1):156-161. doi: 10.1097/TP.0000000000004271. Epub 2022 Aug 2. Transplantation. 2023. PMID: 35996072
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis.
Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F; Special Interest Group on Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Guarino M, et al. Dig Liver Dis. 2018 Nov;50(11):1105-1114. doi: 10.1016/j.dld.2018.08.001. Epub 2018 Aug 11. Dig Liver Dis. 2018. PMID: 30170908 Free article. Review.
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis.
Sacco R, Ramai D, Tortora R, di Costanzo GG, Burlone ME, Pirisi M, Federico P, Daniele B, Silletta M, Gallo P, Cocuzza C, Russello M, Cabibbo G, Rancatore G, Cesario S, Masi G, Marzi L, Mega A, Granito A, Pieri G, Giannini EG, Paolillo R, Gadaleta-Caldarola G, Dadduzio V, Giordano G, Giacomelli L, Papa S, Renzulli M, Maida M, Ghidini M, Borzio M, Facciorusso A; A.I.G.O. (Italian Association of Hospital Gastroenterologists). Sacco R, et al. Among authors: di costanzo gg. Cancers (Basel). 2023 Jan 6;15(2):381. doi: 10.3390/cancers15020381. Cancers (Basel). 2023. PMID: 36672330 Free PMC article.
Refining sorafenib therapy: lessons from clinical practice.
Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S, Cammà C, Bruzzi P, Danesi R, Spandonaro F, Boni C, Santoro A, Colombo M. Bolondi L, et al. Among authors: di costanzo gg. Future Oncol. 2015;11(3):449-65. doi: 10.2217/fon.14.261. Epub 2014 Oct 31. Future Oncol. 2015. PMID: 25360997 Free article. Review.
75 results